target price for AbbVie stock based on DCF / EBITDA multiple analysis (my table and assumptions). Standard & Poor's and S&P are registered trademarks of Standard & Poor's Financial Services LLC and Dow Jones is a registered trademark of Dow Jones Trademark Holdings LLC. All Rights Reserved. And we remain confident in our ability to achieve total sales of more than $9 billion by 2029. AbbVie projected sales - immunology (my forecasts and assumptions). The eye-disease markets are very large - Regeneron's Eylea is a >$7bn per annum selling drug and AMD markets are >$20bn in size. The average analyst rating for AbbVie stock from 34 stock analysts is "Buy". What guidance has AbbVie issued on next quarter's earnings? With AbbVie's revenues accelerating past $80bn in 2030 (by my calculation), and cash flow generated in that year being >$25bn, after applying discount factors for each year I reach a price target of $176 - the average of DCF - $162 per share - and EBITDA - $189 per share - calculations. Analysts have tipped the drug to achieve peak sales of $2.75bn, and although the emergence of CAR-T therapies and some concerns around safety - notably cases of cytokine release syndrome ("CRS') - persist, this revenue figure is achievable in my view. CFDs are complex leveraged instruments and come with a high risk of losing money. AbbVie will have to drop its price point to compete with the generics however, plus there is the 10% of the market it is not covered for, so an overall 20% decline in revenues in 2023 seems accurate. The CEO, speaking at a fireside chat during the conference, commented: we remain well-positioned to absorb the impact from the Humira LOE and quickly return to strong growth starting in 2025. In the U.S. dermatology segment, where approximately 30% of patients exhibit both skin and joint involvement, Skyrizi is already achieving an in-play patient share of nearly 20%. The company reported its first revenue for Botox competitor Daxxify. The weighted average cost of capital I estimate to be 9.6% - I tend to use a WACC of 10% for most Big Pharma analysis. Rinvoq's progress has been a little more circumspect, but almost as impressive. Sales of the drug reached $19.9bn in 2018 and were $19.2bn, $19.8bn and $20.6bn in 2019, 2020, and 2021 respectively. To be sure, AbbVie is modeling for a tough year in 2023 for the aesthetics market. Although Wallet Investor did not provide targets for 2030, its longer-term Abbvie stock prediction expected the price to hit $300.386 in June 2027. AbbVie's Q2'22 earnings threw up some positives and negatives for investors to contemplate. AbbVie saw a increase in short interest in February. Shares of ABBV stock can be purchased through any online brokerage account. The Abbvie stock forecast for 2025 had the price at $259.018. I wrote this article myself, and it expresses my own opinions. The company has been increasing its dividend for 51 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. Disclosure: I/we have a beneficial long position in the shares of BMY, GILD, ABBV either through stock ownership, options, or other derivatives. Shares are consolidating with a buy. Both of these assets appear to be doing the job they were intended for - protecting AbbVie's dominance in various auto-immune markets - and now represent ~13% of AbbVie's total revenue generation. Past performance is no guarantee of future results. AbbVie Inc. is a US-based biopharma company with global operations. There has been a raft of price-moving news for Abbvie, which may positively affect the stock price. What is ABBV's Earnings Per Share (EPS) forecast for 2023-2025? The S&P 500 (US500) lost 9.1%, the Dow Jones (US30) slid 9.7%, and the Nasdaq Composite fell 23% during the same period. AbbVie has received a consensus rating of Hold. Their ABBV share price forecasts range from $140.00 to $200.00. On average, analysts rate AbbVie stock as a buy. It now expects full-year profit in the range of $13.92-$14.12 a share. I am not receiving compensation for it (other than from Seeking Alpha). Earnings for AbbVie are expected to decrease by -0.55% in the coming year, from $11.00 to $10.94 per share. AbbVie's post-Humira LOE plans are not riskless, and its targets are ambitious, but nevertheless I see no harm in picking up shares in the Pharma at the current price, accepting a generous 4% dividend, and likely benefitting from share repurchases and a steadily growing share price until 2030. In other words, management believes the LOE of Humira - despite it being the world's best-selling drug - will not hinder growth at the company. Neuroscience is one of AbbVie's most intriguing divisions and perhaps the hardest to model. The company employs 50,000 workers across the globe. As well as the stock price gains AbbVie has always paid a handsome dividend - which has increased by 270% since the Pharma's inception, currently paying $1.48 per quarter, for a current yield of 4% - the highest in the large Pharmaceutical sector. Please. Discovery Company. Whether these factors make ABBV a good investment for you or not will depend on your portfolio composition, investment goals and risk profile, among other factors. Slide from JPM Conference 2022 presentation. This has been in spite of a string of macroeconomic headwinds such as the ongoing Russia-Ukraine war that has contributed to record high inflation in the US and the UK, and the companys psoriatic arthritis drug Adalimumab, known as Humira, facing biosimilar rivals in the US from 2023. In 2022, Humira revenues will likely reach $21bn, which will see the drug overtake cholesterol-lowering Lipitor as the best-selling drug of all-time. To see all exchange delays and terms of use please see Barchart's disclaimer. The company also successfully completed the acquisition of Syndesi Therapeutics SA in March. I am not receiving compensation for it (other than from Seeking Alpha). Projections are based on making fundamental and technical studies of the ABBV stock price performance. Although the company has admitted that 2023 earnings will likely be down in 2022 - guidance for last year is for earnings per share ("EPS') of $13.84 - $13.88 on an adjusted diluted basis, versus $12.7 in 2021 - Gonzalez and his team were making some bold promises to investors at this year's JP Morgan Healthcare conference. The company is focused on research and has a number of collaborations and partnerships to that end. For ABBVIE INC stock forecast for 2023, 10 predictions are offered for each month of 2023 with average ABBVIE INC stock forecast of $156.58, a high forecast of $160.07, and a low forecast of $152.24. Fortunately for AbbVie shareholders Gonzalez and his management team have had many more years than expected to prepare for Humira's Loss of Exclusivity ("LOE"), and it has never been the Pharma's ambition to build its business around a single, all-conquering but time-limited drug. My EPS figure increases slightly between 2022 and 2023, whilst AbbVie has suggested it will be down slightly before beginning to accelerate towards the end of the decade, as revenues correspondingly begin to climb sharply once the worst of the Humira LOE is over. All rights reserved. Note that analysts ABBV stock forecasts can be wrong. And never invest or trade money you cannot afford to lose. 2023 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Always do your own research on a stocks price performance and predictions before making an investment. Aesthetics was propped up by growing sales of Botox - up 12% year-on-year to $678m, but let down by sales of Juvederm, which management put down to lockdown regulations in China, and the "suspension" of operations in Russia. Specifically, they have bought $0.00 in company stock and sold $23,102,528.00 in company stock. The 21 analysts offering 12-month price forecasts for Abbvie Inc have a median target of 165.00, with a high estimate of 200.00 and a low estimate of 135.00. The company can be reached via phone at (847) 932-7900 or via fax at 302-655-5049. The average price target is $163.64 with a high forecast of $190.00 and a low forecast of $133.00. According to 34 stock analysts, the average 12-month stock price forecast for AbbVie stock is $166.14, which predicts an increase of 7.62%. Naturally, if there is a more effective and safe drug than Humira available for the same indication, then physicians are likely to prescribe it over Humira, or a Humira biosimilar. I/we have a beneficial long position in the shares of ABBV, BMY either through stock ownership, options, or other derivatives. According to analysts' consensus price target of $161.12, AbbVie has a forecasted upside of 3.2% from its current price of $156.06. This could present more profit potential for drugmakers as well as investors. The Large Pharma sector performed remarkably well in 2022, with the "Big 8" delivering an average ~15% gain whilst the S&P 500 index fell in value, and the biotech sector was in turmoil. Dow Jones: The Dow Jones branded indices are proprietary to and are calculated, distributed and marketed by DJI Opco, a subsidiary of S&P Dow Jones Indices LLC and have been licensed for use to S&P Opco, LLC and CNN. For the next year, analysts predict that Free Cash Flow will reach 6.91B - an increase of 1.94%. Since then, ABBV stock has decreased by 3.4% and is now trading at $156.06. I suspect Eye Care is a division AbbVie can turn around given time, and I feel that with regards to oncology, where AbbVie has the strongest pipeline assets - lymphoma bispecific Epcoritamab may be approved to treat large B-cell lymphoma, and peak sales estimates range from $1.5 - $3bn, although AbbVie will not earn all of that since the product is co-developed with Genmab. This means that . According to CompaniesMarketCap, the biopharmas market capitalisation stood at $272.38bn, making it the worlds 30th most valuable company. Within the oncology division sales of Imbruvica fell 17% year-on-year. Currently, AbbVie sees a significantly higher portion of every dollar end up as cash to do with what they please. Always conduct your own due diligence before investing. Johnson & Johnson Free Cash Flow Forecast for 2023 - 2025 - 2030. Furthermore, it seems sales of Lupron and Synthroid have joined the "All Other" section, which has generated $2.2bn of revenues in the first half of 2022, versus $1.5bn in the first half of 2021. Other products such as Mavyret and Creon appear to have many more years of blockbuster sales ahead of them, although it is interesting to note that AbbVie no longer reports revenues from its Women's Health division, and scarcely mentions it. It is in business to discover, develop, manufacture and market pharmaceuticals globally but in a way that best serves the needs of patients and the global community. The firm's revenue for the quarter was up 1.6% compared to the same quarter last year. And it couldnt be more wrong! I have not managed to match management's ambitious high-single-digit growth figures from 2025 - 2023, despite anticipating 6% growth for nearly all products in that period. AbbVie has a P/B Ratio of 15.97. Skyrizi is a collaboration between Boehringer Ingelheim and AbbVie, with AbbVie leading development and commercialisation globally. This indicates that the company will be able to sustain or increase its dividend. There are currently 9 hold ratings and 7 buy ratings for the stock. ABBV Stock 12 Months Forecast. In the last two years, Aurora Cannabis's Revenue has fallen from C$245.54M to C$245.25M - a 0.12% decrease. Thus, it is likely that ABBV will continue to find support on the dips in this type of market environment.. It should be noted however that, with ~$12bn near-term debt falling due, and long-term debt of ~$61bn - most of it due to the $66bn acquisition of Allergan, completed in 2020, AbbVie has some hefty interest expense payments to make - $15bn between 2022 and 2027, I estimate, and the level of debt makes it tough for the company to invest in M&A deals. The five-year dividend growth rate is just below 18%. According to AbbVie CEO Rick Gonzalez, speaking on the Q2'22 earnings call, "Skyrizi's total prescription share of the U.S. biological market (in psoriasis) has increased to approximately 26%", and". AbbVie Stock Forecast 2022 - 2025 - 2030 | StockForecast.com GB If youre new to trading, then youve probably heard the wrong thing about optionsthat theyre risky, unpredictable, or difficult. The total revenue in 2021 was $56.20 billion with a 31% operating margin. My calculation is that Humira revenues in 2023 will be 80% of the 2022 figure, or $16.7bn. High institutional ownership can be a signal of strong market trust in this company. As we look beyond 2025, we expect combined sales for Skyrizi and Rinvoq to exceed the peak revenues achieved by Humira, which was more than $21 billion. Over the years, AbbView Inc. has made numerous acquisitions. AbbVie declared a quarterly dividend on Thursday, February 16th. Bringing RGX314 would be a coup for AbbVie although I am forecasting for only $2bn in peak revenues in 2030 as a hedge against the risk that this candidate does not make it to market on safety grounds. AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV.". Pessimistic target level: 151.42 Optimistic target level: 154.48 ABBV (ABBV) Monthly Stock Prediction for 2023 Full forecast for 2023 AbbVie forecast for this year Eye Care, Other products Division Projected Revenues to 2030 (my table and assumptions ). It revealed that patients with moderate to severe Crohns disease receiving Abbvies Rinvoq achieved steroid-free clinical remission in significantly higher numbers than patients receiving a placebo. AbbVie product revenue forecasts to 2030. Year-to-date, the stock was up slightly more than 12% while benchmark global indices have all fallen sharply amid surging inflation, interest rate hikes and slowdown worries. Compare Top Brokerages Here. The surge in revenues can primarily be attributed to its Allergan. All times are ET. Management has previously stated that it expects total revenues to decline in 2023 following the Humira LOE, followed by a return to growth in 2024, and a "high single digit CAGR" maintained through the remainder of the decade. Capital Com Australia Pty Ltd (ABN 47 625 601 489) is a company registered in Australia and regulated by the Australian Securities and Investments Commission (ASIC) under AFSL 513393. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Receive regular, detailed analysis focused on biotech and healthcare stocks. Finally, AbbVie was able to raise its financial . View institutional ownership trends. These are Immunology, Oncology, Neurology, Virology and Eye Care. Our daily ratings and market update email newsletter. In the next year, analysts predict that Revenue will reach C$253.83M - an increase of 3.50%. Moreover, with surging demand, rising investments in research and development, and increasing e-pharmacy channels, the industry is well-positioned for significant growth New research suggests Depakote ingredient could have a new clinical function. Abbvie Stock Forecast 2023 In the Biopharmaceutical Industry, Abbvie has been able to create a leadership position in the market in each business segment with different brand names in different business categories like Immunology, Hematologic Oncology, Neuroscience, Aesthetics, and Eye Care. In 2022, the company will most likely boast 12 "blockbuster" (>$1bn per annum) selling assets, driving ~$48bn of revenues between them, with Humira being the only drug that faces a near term patent expiry, whilst AbbVie is promising at least 6 or 7 major new product launches by 2026. AbbVie stock forecast 2022 - 2025 - 2030 with analysis AbbVie stock stood at $162.110000610352 on 2022-03-31. forecast for 2023 is $159.42, forecast for 2024 is $156.65, forecast for 2025 is $139.68, forecast for 2026 is $124.48, . The consensus rating was moderate buy based on 16 analysts ratings, with 10 recommending buy, five hold and sell. All rights reserved. It is generally accepted however that 2023 will see the entrants into the US market of several generic versions of Humira - which works by inhibiting Tumor Necrosis Factor ("TNF"), an inflammation causing protein - from the likes of Viatris (VTRS), Organon (OGN), Pfizer (PFE), Amgen (AMGN), and several more companies involved in the development and sale of generic or biosimilar drugs. The difference between trading assets and CFDs. Find me at my marketplace channel, Haggerston BioHealth - model portfolio + 4 exclusive stock tips every week. What is AbbVie's stock price forecast for 2023? AbbVie stock was up after posting a mixed fourth-quarter earnings report, but with the company's patent expiring on Humira, the stock is a hold, February 24, 2023|americanbankingnews.com, February 23, 2023|americanbankingnews.com. With no LOEs on the horizon, it is relatively plain sailing for the company ex-Humira, and the performance of Skyrizi and Rinvoq - to date at least - suggests management does have this massive patent cliff covered. Trading CFDs is high risk and is not suitable for everyone. If signs point to that happening I will likely be revising my target price upwards again, but I am playing it more conservative as nobody truly knows the scale of losses after the Humira LOE. 8.05% Is this happening to you frequently? Aurora Cannabis Revenue Forecast for 2023 - 2025 - 2030. Ever since its split from Abbott Laboratories (ABT) in 2012 AbbVie (NYSE:ABBV) has delivered strong returns for investors - its stock price having risen overall from $30, to $149 per share at the time of writing - trading down slightly from its all-time high of >$160 achieved in early December last year. This indicates that AbbVie will be able to sustain or increase its dividend. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. The development of these 2 drugs has been very quick by drug development standards, and to date both have performed exceptionally well. Migraine therapy Ubrelvy is a future blockbuster, Gonzalez believes, as is Qulipta, in the same indication. About the AbbVie, Inc. stock forecast. Having so much debt in a prevailing inflationary environment is also unattractive. Insiders that own company stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Carrie C Strom, Carrie C Strom, Elaine K Sorg, Henry O Gosebruch, Jeffrey Ryan Stewart, Laura J Schumacher, Michael Severino, Perry C Siatis, Richard A Gonzalez, Robert A Michael, Roxanne S Austin, Scott T Reents, Timothy J Richmond and Timothy J Richmond. On the negative side of things, we can see that AbbVie is no longer breaking out sales within its Women's Health division, with revenues lumped into the "all other section, presumably. The most recent increase was . View the best growth stocks for 2023 here. The majority of the biosimilar (more sophisticated versions of generic drugs) imitations of Humira that will contest for market share with the original will launch around the middle of 2023, including versions developed by Pfizer (PFE), Boehringer Ingelheim, Organon (OGN), Biocon, Coherus Biosciences (CHRS) and Sandoz, whilst Amgen's (AMGN) Amjevita is permitted to launch in January.
Gray's Creek High School Football Tickets,
Which Of The Following Statements About Sodium Intake Is True?,
Grateful Dead Live Albums Ranked,
Comcast Nesn Plus Channel Number,
Articles A
abbvie stock forecast 2030
